Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: A review

AIDS Research and Therapy

Volumn 6, Issue , 2009, Pages

  Meenakshisundaram, Ramachandran ^a   Sweni, Shah ^b,d   Thirumalaikolundusubramanian, Ponniah ^c  

^a MADRAS MEDICAL COLLEGE   (India)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c Chennai Medical College Hospital   (India)

^d NONE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID OXIDASE; ANTIRETROVIRUS AGENT; INSECT VENOM; PHOSPHOLIPASE A2; PROTEINASE; SNAKE VENOM;

ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; VIRUS INHIBITION; VIRUS LOAD;

EID: 78649274562     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-6-25     Document Type: Review

References (44)

1. Koh D, Armugam A, Jeyaseelan K. Snake venom components and their applications in biomedicine. Cell Mol Life Sci 2006, 63(24):3030-3041. 10.1007/s00018-006-6315-0, 17103111.
2. Patlak M. From viper's venom to drug design: treating hypertension. FASEB J 2004, 18(3):421. 10.1096/fj.03-1398bkt, 15003987.
3. Marsh NA. Diagnostic uses of snake venom. Haemostasis 2001, 31(3-6):211-217.
4. Chen ZX, Zhang HL, Gu ZL, Chen BW, Han R, Reid PF, Raymond LN, Qin ZH. A long-form alpha-neurotoxin from cobra venom produces potent opioid-independent analgesia. Acta Pharmacol Sin 2006, 27(4):402-408. 10.1111/j.1745-7254.2006.00293.x, 16539838.
5. Pu XC, Wong PT, Gopalakrishnakone P. A novel analgesic toxin (hannalgesin) from the venom of king cobra (Ophiophagus hannah). Toxicon 1995, 33(11):1425-1431. 10.1016/0041-0101(95)00096-5, 8744982.
6. Faure G, Harvey AL, Thomson E, Saliou B, Radvyani F, Bon C. Comparison of crotoxin isoforms reveals that stability of the complex plays a major role in its pharmacological action. Eur J Biochem 1993, 214(2):491-496. 10.1111/j.1432-1033.1993.tb17946.x, 8513799.
7. Alrajhi AA, Almohaizeie A. Snake venom preparation for drug-resistant human immunodeficiency virus. Ann Saudi Med 2008, 28(4):292-293. 10.4103/0256-4947.51714, 18545005.
8. Samayz. , http://www.samayz-ksa.com/index.html
9. Meenakshisundaram R, Uma A, Thirumalaikolundusubramanian P. RE: Snake venom preparation for drug-resistant human immunodeficiency virus. Ann Saudi Med 2009, 29(2):159. 10.4103/0256-4947.51791, 19318759.
10. Wachinger M, Kleinschmidt A, Winder D, von Pechmann N, Ludvigsen A, Neumann M, Holle R, Salmons B, Erfle V, Brack-Werner R. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J Gen Virol 1998, 79(Pt 4):731-740.
11. Fenard D, Lambeau G, Valentin E, Lefebvre JC, Lazdunski M, Doglio A. Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells. J Clin Invest 1999, 104(5):611-618. 10.1172/JCI6915, 10487775, 408539.
12. Kim JO, Chakrabarti BK, Guha-Niyogi A, Louder MK, Mascola JR, Ganesh L, Nabel GJ. Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2. J Virol 2007, 81(3):1444-1450. 10.1128/JVI.01790-06, 1797512, 17093191.
13. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(6686):648-659. 10.1038/31405, 9641677.
14. Sönnerborg A, Johansson B. The neurotoxin-like sequence of human immunodeficiency virus GP120: A comparison of sequence data from patients with and without neurological symptoms. Virus Genes 1993, 7(1):23-31. 10.1007/BF01702346, 8470367.
15. Neri P, Bracci L, Rustici M, Santucci A. Sequence homology between HIV gp120, rabies virus glycoprotein, and snake venom neurotoxins. Archives of Virology 1990, 114(3):265-269. 10.1007/BF01310756, 2241576.
16. da Silva JO, Fernandes RS, Ticli FK, Oliveira CZ, Mazzi MV, Franco JJ, Giuliatti S, Pereira PS, Soares AM, Sampaio SV. Triterpenoid saponins, new metalloprotease snake venom inhibitors isolated from Pentaclethra macroloba. Toxicon 2007, 50(2):283-291. 10.1016/j.toxicon.2007.03.024, 17517426.
17. Esperanza NeuroPeptides. , http://www.esperanzapeptide.net/news.php
18. Zhang YJ, Wang JH, Lee WH, Wang Q, Liu H, Zheng YT, Zhang Y. Molecular characterization of Trimeresurus stejnegeri venom L-amino acid oxidase with potential anti-HIV activity. Biochem Biophys Res Commun 2003, 309(3):598-604. 10.1016/j.bbrc.2003.08.044, 12963032.
19. Du XY, Clemetson KJ. Snake venom L-amino acid oxidases. Toxicon 2002, 40(6):659-665. 10.1016/S0041-0101(02)00102-2, 12175601.
20. Brown AE, Vahey MT, Zhou SY, Chung RC, Ruiz NM, Hofheinz D, Lane JR, Mayers DL. Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. The RV43 Study Group. J Infect Dis 1995, 172(4):1091-1095.
21. Ophidia products Inc. , http://ophidia.com/novel_synth.html
22. Fenard DL, Valentin E, Lefebvre JC, Lazdunski M, Doglio A. Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells. J Clin Invest 1999, 104:611-618. 10.1172/JCI6915, 408539, 10487775.
23. Tandon V, Kapoor B, Bano G, Gupta S, Gillani Z, Kour D. P-glycoprotein: Pharmacological relevance. Indian Journal of Pharmacology 2006, 38(1):13-24.
24. Damaj MI, Meyer EM, Martin BR. The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology 2000, 39(13):2785-2791. 10.1016/S0028-3908(00)00139-8, 11044748.
25. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs 2001, 10(10):1819-1830. 10.1517/13543784.10.10.1819, 11772288.
26. Soares AM, Marcussi S, Stabeli RG, Franca SC, Giglio JR, Ward RJ, Arantes EC. Structural and functional analysis of BmjMIP, a phospholipase A2 myotoxin inhibitor protein from Bothrops moojeni snake plasma. Biochem Biophys Res Commun 2003, 302(2):193-200. 10.1016/S0006-291X(03)00155-4, 12604331.
27. Farooqui AA, Litsky ML, Farooqui T, Horrocks LA. Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Res Bull 1999, 49(3):139-153. 10.1016/S0361-9230(99)00027-1, 10435777.
28. Samsa GP, Matchar DB, Williams GR, Levy DE. Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT). J Eval Clin Pract 2002, 8(1):61-70. 10.1046/j.1365-2753.2002.00315.x, 11882102.
29. Yeh CH, Peng HC, Yang RS, Huang TF. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. Molecular pharmacology 2001, 59(5):1333-1342.
30. Basavarajappa BS, Gowda TV. Comparative characterization of two toxic phospholipases A2 from Indian cobra (Naja naja naja) venom. Toxicon 1992, 30(10):1227-1238. 10.1016/0041-0101(92)90439-C, 1279838.
31. Cura JE, Blanzaco DP, Brisson C, Cura MA, Cabrol R, Larrateguy L, Mendez C, Sechi JC, Silveira JS, Theiller E, et al. Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. Clin Cancer Res 2002, 8(4):1033-1041.
32. Costa LA, Miles HA, Diez RA, Araujo CE, Coni Molina CM, Cervellino JC. Phase I study of VRCTC-310, a purified phospholipase A2 purified from snake venom, in patients with refractory cancer: safety and pharmacokinetic data. Anti-cancer drugs 1997, 8(9):829-834. 10.1097/00001813-199710000-00003, 9402309.
33. Bazzo R, Tappin MJ, Pastore A, Harvey TS, Carver JA, Campbell ID. The structure of melittin. A 1H-NMR study in methanol. Eur J Biochem 1988, 173(1):139-146. 10.1111/j.1432-1033.1988.tb13977.x, 3356186.
34. Boman HG. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995, 13:61-92. 10.1146/annurev.iy.13.040195.000425, 7612236.
35. Wade D, Andreu D, Mitchell SA, Silveira AM, Boman A, Boman HG, Merrifield RB. Antibacterial peptides designed as analogs or hybrids of cecropins and melittin. Int J Pept Protein Res 1992, 40(5):429-436.
36. Marcos JF, Beachy RN, Houghten RA, Blondelle SE, Perez-Paya E. Inhibition of a plant virus infection by analogs of melittin. Proc Natl Acad Sci USA 1995, 92(26):12466-12469. 10.1073/pnas.92.26.12466, 40378, 8618922.
37. Baghian A, Jaynes J, Enright F, Kousoulas KG. An amphipathic alpha-helical synthetic peptide analogue of melittin inhibits herpes simplex virus-1 (HSV-1)-induced cell fusion and virus spread. Peptides 1997, 18(2):177-183. 10.1016/S0196-9781(96)00290-2, 9149288.
38. Esser AF, Bartholomew RM, Jensen FC, Muller-Eberhard HJ. Disassembly of viral membranes by complement independent of channel formation. Proc Natl Acad Sci USA 1979, 76(11):5843-5847. 10.1073/pnas.76.11.5843, 411748, 93283.
39. Wachinger M, Saermark T, Erfle V. Influence of amphipathic peptides on the HIV-1 production in persistently infected T lymphoma cells. FEBS letters 1992, 309(3):235-241. 10.1016/0014-5793(92)80780-K, 1516693.
40. Fenard D, Lambeau G, Maurin T, Lefebvre JC, Doglio A. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol Pharmacol 2001, 60(2):341-347.
41. Villarubia VGCL, Diez RA. Secreted phospholipases A2 (sPLA2): friends or foes? Are they actors in antibacterial and anti-HIV resistance?. Med Clin (Barc) 2004, 123(19):749-757. 10.1157/13069312, 15574291.
42. Valentin E, Ghomashchi F, Gelb MH, Lazdunski M, Lambeau G. Novel human secreted phospholipase A(2) with homology to the group III bee venom enzyme. J Biol Chem 2000, 275(11):7492-7496. 10.1074/jbc.275.11.7492, 10713052.
43. Koduri RS, Gronroos JO, Laine VJ, Le Calvez C, Lambeau G, Nevalainen TJ, Gelb MH. Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A(2). J Biol Chem 2002, 277(8):5849-5857. 10.1074/jbc.M109699200, 11694541.
44. Stranford SA, Skurnick J, Louria D, Osmond D, Chang SY, Sninsky J, Ferrari G, Weinhold K, Lindquist C, Levy JA. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 1999, 96(3):1030-1035. 10.1073/pnas.96.3.1030, 15345, 9927688.